 |
|
Further Observations on Use of Warfarin Sodium in Anticoagulant Therapy
DALLAS V. CLATANOFF, M.D.;
OVID O. MEYER, M.D.
AMA Arch Intern Med. 1956;97(6):753-757.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Recent reports * have indicated that therapeutic hypoprothrombinemia may be produced and maintained safely and effectively by the administration of the 4-hydroxycoumarin compound, warfarin sodium. The rapidity of onset and duration of action of warfarin sodium has suggested that perhaps in instances where prolonged anticoagulant therapy is anticipated warfarin sodium could be administered with less frequency in somewhat larger doses, obviating the necessity for a daily prothrombin determination. This would appear to be a distinct advantage if, after a period of careful observation, a dose could be administered every three or four days that might be predicted with a reasonable degree of accuracy to maintain the prothrombin concentration in an acceptable therapeutic range. Concomitant with good predictability a lessening of the frequency for prothrombin determinations would be realized, with resultant economy.
Our clinical studies were directed by this premise, and presentation of these observations is given, together with a comparison of
. . . [Full Text PDF of this Article]
Author Affiliations
Madison, Wis.
From the Department of Medicine, University of Wisconsin Medical School. Trainee, National Cancer Institute, during the time of this work (Dr. Clatanoff); present address: Thorndike Memorial Laboratory, Boston City Hospital, Boston 18.
Footnotes
Submitted for publication Dec. 15, 1955.
This study was supported in part by the Research Committee of the Graduate School from funds supplied by the Wisconsin Alumni Research Foundation.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
|
